Modulation of Lymphoma Cell Survival and antigen Presentation by Inorganic arsenic

School Name

Governor's School for Science & Mathematics

Grade Level

12th Grade

Presentation Topic

Cell and Molecular Biology

Presentation Type

Mentored

Mentor

Mentor: Azizul Haque, Medical University of South Carolina

Oral Presentation Award

3rd Place

Written Paper Award

2nd Place

Abstract

Inorganic arsenic is a known carcinogen and a widespread water pollutant. Humans exposed to arsenic through drinking water are prone to develop malignancies such as skin cancer, lung cancer, colon cancer and bladder cancer, but rarely develop B-cell lymphomas. Modification of B-cell lymphoma antigen presentation by the arsenic may contribute to this trend of lymphoma resistance. In this study, B-cell lymphoma was treated with arsenic and its antigen presentation to T-cells was measured. Arsenic’s potential as an immunotherapeutic treatment was studied by observing whether it can kill lymphoma cells at high concentrations while enhancing immune responses at sublethal doses. Preliminary results are promising, showing lymphoma cell death and an increase in immune cell response.

Location

Wall 209

Start Date

3-25-2017 9:00 AM

Presentation Format

Oral and Written

Group Project

No

COinS
 
Mar 25th, 9:00 AM

Modulation of Lymphoma Cell Survival and antigen Presentation by Inorganic arsenic

Wall 209

Inorganic arsenic is a known carcinogen and a widespread water pollutant. Humans exposed to arsenic through drinking water are prone to develop malignancies such as skin cancer, lung cancer, colon cancer and bladder cancer, but rarely develop B-cell lymphomas. Modification of B-cell lymphoma antigen presentation by the arsenic may contribute to this trend of lymphoma resistance. In this study, B-cell lymphoma was treated with arsenic and its antigen presentation to T-cells was measured. Arsenic’s potential as an immunotherapeutic treatment was studied by observing whether it can kill lymphoma cells at high concentrations while enhancing immune responses at sublethal doses. Preliminary results are promising, showing lymphoma cell death and an increase in immune cell response.